QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / May 10, 2024 / If you suffered a loss on your QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ:QDEL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/quidelortho-lawsuit-submission-form?prid=79305&wire=1 or contact Joseph E. Levi, Esq.

June 11, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against QDEL

NEW YORK , May 10, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation (NASDAQ: QDEL) between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important June 11, 2024 lead plaintiff deadline. SO WHAT: If you purchased QuidelOrtho common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONAL TRIAL COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - QDEL

NEW YORK, NY / ACCESSWIRE / May 10, 2024 / If you suffered a loss on your QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ:QDEL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/quidelortho-lawsuit-submission-form?prid=79255&wire=1 or contact Joseph E. Levi, Esq.

June 11, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - QDEL

NEW YORK , May 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ: QDEL). Shareholders who purchased shares of QDEL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Investors in QuidelOrtho Corporation f/k/a Quidel Corporation Should Contact The Gross Law Firm Before June 11, 2024 to Discuss Your Rights - QDEL

NEW YORK, NY / ACCESSWIRE / May 9, 2024 / If you suffered a loss on your QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ:QDEL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/quidelortho-lawsuit-submission-form?prid=79094&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds QuidelOrtho Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 11, 2024 – QDEL

QuidelOrtho's (QDEL) first-quarter results reflect growth in revenues, excluding the COVID-19 revenue impact.

QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall

NEW YORK, NY / ACCESSWIRE / May 9, 2024 / If you suffered a loss on your QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ:QDEL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/quidelortho-lawsuit-submission-form?prid=79038&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) should contact Levi & Korsinsky about pending Class Action - QDEL

QuidelOrtho Corporation (NASDAQ:QDEL ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Juliet Cunningham – Vice President-Investor Relations Brian Blaser – President and Chief Executive Officer Mike Iskra – Executive Vice President and Chief Commercial Officer Joe Busky – Chief Financial Officer Conference Call Participants Jack Meehan – Nephron Research Maggie Boeye – William Blair Andrew Cooper – Raymond James Conor McNamara – RBC Patrick Donnelly – Citi Casey Woodring – JPMorgan Operator Welcome to the QuidelOrtho First Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.

QuidelOrtho Corporation (QDEL) Q1 2024 Earnings Call Transcript

While the top- and bottom-line numbers for QuidelOrtho (QDEL) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About QuidelOrtho (QDEL) Q1 Earnings

QuidelOrtho (QDEL) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $1.80 per share a year ago.

QuidelOrtho (QDEL) Q1 Earnings and Revenues Top Estimates

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first quarter ended March 31, 2024. “During the first quarter, we achieved solid business performance with 6% top-line constant currency revenue growth across our global regions, excluding COVID-19 revenue,” said.

QuidelOrtho Reports First Quarter 2024 Financial Results

NEW YORK, NY / ACCESSWIRE / May 8, 2024 / If you suffered a loss on your QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ:QDEL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/quidelortho-lawsuit-submission-form?prid=78761&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK , May 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ: QDEL). Shareholders who purchased shares of QDEL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Investors who lost money on QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) should contact The Gross Law Firm about pending Class Action - QDEL

NEW YORK, NY / ACCESSWIRE / May 6, 2024 / If you suffered a loss on your QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ:QDEL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/quidelortho-lawsuit-submission-form?prid=78349&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for QuidelOrtho (QDEL), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Unveiling QuidelOrtho (QDEL) Q1 Outlook: Wall Street Estimates for Key Metrics

NEW YORK, NY / ACCESSWIRE / May 3, 2024 / If you suffered a loss on your QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ:QDEL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/quidelortho-lawsuit-submission-form?prid=78080&wire=1 or contact Joseph E. Levi, Esq.

QuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 11, 2024 to Discuss Your Rights – QDEL

NEW YORK , May 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation (NASDAQ: QDEL) between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important June 11, 2024 lead plaintiff deadline. SO WHAT: If you purchased QuidelOrtho common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - QDEL

NEW YORK , May 3, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL) and reminds investors of the June 11, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In QuidelOrtho To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in QuidelOrtho stock or options between February 18, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of QuidelOrtho

NEW YORK, NY / ACCESSWIRE / May 3, 2024 / If you suffered a loss on your QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ:QDEL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/quidelortho-lawsuit-submission-form?prid=78034&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 11, 2024 in QuidelOrtho Corporation f/k/a Quidel Corporation Lawsuit - QDEL

NEW YORK , May 3, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ: QDEL). Shareholders who purchased shares of QDEL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors - Contact The Gross Law Firm

NEW YORK, NY / ACCESSWIRE / May 2, 2024 / If you suffered a loss on your QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ:QDEL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/quidelortho-lawsuit-submission-form?prid=77970&wire=1 or contact Joseph E. Levi, Esq.

QuidelOrtho Corporation f/k/a Quidel Corporation Class Action: Levi & Korsinsky Reminds QuidelOrtho Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 11, 2024 – QDEL

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care settings, clinical labs and transfusion medicine, announced the Company's Board of Directors (the “Board”) has appointed Brian J. Blaser as President and Chief Executive Officer (“CEO”) effective May 6. In addition to his appointment as President and CEO, Mr. Blaser will join the Board, effective May 15,.

QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer

NEW YORK, NY / ACCESSWIRE / May 1, 2024 / If you suffered a loss on your QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ:QDEL) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/quidelortho-lawsuit-submission-form?prid=77793&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 11, 2024 in QuidelOrtho Corporation f/k/a Quidel Corporation Lawsuit – QDEL

LOS ANGELES , May 1, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ: QDEL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against QuidelOrtho Corporation and Encourages Investors with Losses to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $QDEL #QDEL--Robbins LLP is Investigating the Allegations that QuidelOrtho Corporation (QDEL) Misled Investors Regarding Demand for its Product.

News for QuidelOrtho Corp Stock (QDEL)